Status:
COMPLETED
Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis
Lead Sponsor:
Wake Forest University
Collaborating Sponsors:
Abbott
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
6-50 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate whether Biaxin (clarithromycin) improves sputum abnormalities, lung function, and overall feeling of well-being in people with cystic fibrosis (CF). Biaxin is ...
Eligibility Criteria
Inclusion
- diagnosis of CF
- ability to reliably perform spirometry
- FEV1 of 30% predicted at the time of screening
Exclusion
- Mycobacterium in a sputum culture ever recorded
- a respiratory exacerbation requiring IV antibiotics in the 60 days prior
- used a investigational drug or device in the 60 days prior
- significant (\>30ml) of hemoptysis in the past year
- require oxygen or have significant liver or renal disease
Key Trial Info
Start Date :
December 1 2000
Trial Type :
INTERVENTIONAL
End Date :
October 1 2004
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00205634
Start Date
December 1 2000
End Date
October 1 2004
Last Update
August 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157